Duloxetine | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Duloxetine
Health Canada Patents

Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

Contact Supplier

Evonik

Contact Supplier

Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

jdmfs-not-supported-m-2025-04-28

Duloxetine

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

120 API Suppliers, 43 USDMF, 31 CEP/COS, 12 JDMF, 17 EU WC, 26 KDMF, 18 NDC API, 58 Listed Suppliers, $ API Reference Price

120 API Suppliers
43 USDMF
31 CEP/COS
12 JDMF
17 EU WC
26 KDMF
18 NDC API
58 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

34 Intermediate Suppliers

34 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

600 FDF Dossiers, 98 FDA Orange Book, 282 Europe, 40 Canada, 18 Australia, 30 South Africa, 132 Listed Dossiers

600 FDF Dossiers
98 FDA Orange Book
282 Europe
40 Canada
18 Australia
30 South Africa
132 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE, DELAYED REL PELLETS;ORAL - EQ 20MG BASE, CAPSULE, DELAYED REL PELLETS;ORAL - EQ 30MG BASE, CAPSULE, DELAYED REL PELLETS;ORAL - EQ 60MG BASE

CAPSULE, DELAYED REL PELLETS;ORAL - EQ 20MG BASE
CAPSULE, DELAYED REL PELLETS;ORAL - EQ 30MG BASE
CAPSULE, DELAYED REL PELLETS;ORAL - EQ 60MG BASE

RELATED EXCIPIENT COMPANIES

3 Evonik, 1 Rochem International Inc, 16 SPI Pharma, 17 DKSH, 7 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 4 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 6 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 35 BASF, 1 Clariant, 13 Corel Pharma Chem, 3 DFE Pharma, 2 Finar, 14 Gangwal Chemicals, 11 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nomisma Healthcare, 4 Novo Excipients, 2 Pharmatrans-Sanaq, 7 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 11 Roquette, 14 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 6 Sigachi Industries, 2 Silverline Chemicals, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 2 Valens Pharmachem, 2 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

81 Fillers, Diluents & Binders, 75 Coating Systems & Additives, 39 Controlled & Modified Release, 35 Solubilizers, 35 Disintegrants & Superdisintegrants, 32 Direct Compression, 27 Thickeners and Stabilizers, 25 Granulation, 21 Taste Masking, 21 Topical, 18 Chewable & Orodispersible Aids, 18 Parenteral, 17 Lubricants & Glidants, 17 Film Formers & Plasticizers, 13 Co-Processed Excipients, 9 Empty Capsules, 8 Emulsifying Agents, 7 API Stability Enhancers, 6 Rheology Modifiers, 5 Coloring Agents, 5 Surfactant & Foaming Agents, 4 Vegetarian Capsules

81 Fillers, Diluents & Binders
75 Coating Systems & Additives
39 Controlled & Modified Release
35 Solubilizers
35 Disintegrants & Superdisintegrants
32 Direct Compression
27 Thickeners and Stabilizers
25 Granulation
21 Taste Masking
21 Topical
18 Chewable & Orodispersible Aids
18 Parenteral
17 Lubricants & Glidants
17 Film Formers & Plasticizers
13 Co-Processed Excipients
9 Empty Capsules
8 Emulsifying Agents
7 API Stability Enhancers
6 Rheology Modifiers
5 Coloring Agents
5 Surfactant & Foaming Agents
4 Vegetarian Capsules

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 56 News #PharmaBuzz

1 Data Compilation #PharmaFlow
56 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 216 Regulatory FDF Prices, 14 Annual Reports

2 US Medicaid Prescriptions
216 Regulatory FDF Prices
14 Annual Reports

MARKET PLACE

23 APIs, 7 FDF Dossiers

23 APIs
7 FDF Dossiers

PATENTS & EXCLUSIVITIES

20 US Patents, 6 Health Canada Patents

20 US Patents
6 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 11 USP, 10 Others

3 EDQM
11 USP
10 Others

ANALYTICAL

2 BioAnalytical Methods, 2 Analytical Methods

2 BioAnalytical Methods
2 Analytical Methods

$ API Ref.Price (USD/KG) : 229 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 4Gowling Lafleur Henderson LLP

02 2Blank

filter Patent Reset all filters

6 All

01 21302421

02 22153856

03 22344057

filter Product Reset all filters

6 All

01 4Duloxetine Hydrochloride

02 2Blank

filter Dosage Reset all filters

6 All

01 4Delayed-Release Capsule

02 2Blank

filter Exp Date Reset all filters

6 All

01 22009-06-02

02 22015-07-13

03 22019-09-10

Product Main Page

01

Gowling Lafleur Henderson LLP

Duloxetine Hydrochloride

RDD 2025

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

RDD 2025

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-07-13

Date Granted : 2005-05-10

Duloxetine Hydrochloride

Brand Name : CYMBALTA

Patent Number : 2153856

Filing Date : 1995-07-13

Strength per Unit : 30 mg

Dosage Form : Delayed-Release Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-07-13

Date Granted : 2005-05-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowling Lafleur Henderson LLP

Duloxetine Hydrochloride

RDD 2025

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

RDD 2025

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-07-13

Date Granted : 2005-05-10

Duloxetine Hydrochloride

Brand Name : CYMBALTA

Patent Number : 2153856

Filing Date : 1995-07-13

Strength per Unit : 60 mg

Dosage Form : Delayed-Release Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-07-13

Date Granted : 2005-05-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Gowling Lafleur Henderson LLP

Duloxetine Hydrochloride

RDD 2025

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

RDD 2025

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2019-09-10

Date Granted : 2008-11-18

Duloxetine Hydrochloride

Brand Name : CYMBALTA

Patent Number : 2344057

Filing Date : 1999-09-10

Strength per Unit : 30 mg

Dosage Form : Delayed-Release Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2019-09-10

Date Granted : 2008-11-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Gowling Lafleur Henderson LLP

Duloxetine Hydrochloride

RDD 2025

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

RDD 2025

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2019-09-10

Date Granted : 2008-11-18

Duloxetine Hydrochloride

Brand Name : CYMBALTA

Patent Number : 2344057

Filing Date : 1999-09-10

Strength per Unit : 60 mg

Dosage Form : Delayed-Release Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2019-09-10

Date Granted : 2008-11-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Duloxetine Hydrochloride

RDD 2025

Not Confirmed

Country

RDD 2025

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2009-06-02

Date Granted :

Duloxetine Hydrochloride

Brand Name :

Patent Number : 1302421

Filing Date :

Strength per Unit :

Dosage Form :

Human Or VET :

Route of Administration :

Patent Expiration Date : 2009-06-02

Date Granted :

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Duloxetine Hydrochloride

RDD 2025

Not Confirmed

Country

RDD 2025

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2009-06-02

Date Granted :

Duloxetine Hydrochloride

Brand Name :

Patent Number : 1302421

Filing Date :

Strength per Unit :

Dosage Form :

Human Or VET :

Route of Administration :

Patent Expiration Date : 2009-06-02

Date Granted :

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!